FGF19 or FGFR4 functions as a potential therapeutic target for the treatment of HCC patients, which is an active topic in the field of clinical liver oncology (Zhong et al., 2014; Hagel et al., 2015; Repana and Ross, 2015; Sheu et al., 2015; Gao et al., 2017; Joshi et al., 2017; Cui et al., 2018; Kim et al., 2019a; Hatlen et al., 2019; Subbiah and Pal, 2019; Weiss et al., 2019). The gene discussed is FGFR4; the disease is hepatocellular carcinoma.